Frontiers in Bioscience-Elite (Sep 2022)

Cuminaldehyde ameliorates hyperglycemia in diabetic mice

  • Kannan Duraisamy,
  • Pari Leelavinothan,
  • Paari Ellappan,
  • Tulsi Deepak Singh Balaji,
  • Ponnulakshmi Rajagopal,
  • Selvaraj Jayaraman,
  • Shyamaldevi Babu

DOI
https://doi.org/10.31083/j.fbe1404024
Journal volume & issue
Vol. 14, no. 4
p. 24

Abstract

Read online

Background: Animal-fats are rich in long-chain saturated fatty-acids, well known to induct diabetic distress among ingested insulin-insensitive individuals. In the current-study, bovine-fat was fed to selective mice breeds highly sensitized to heavy dietary lipid load. Methods: The later high fat diet (HFD) group indeed undergone diabetic-onset within weeks with a drastically altered feed-behavior pattern. It consumed more food, gained body mass, elevated homeostatic model assessment value and extensively glycosylated Hb transporters. Results: However, the hypothetical test drug (Cuminaldehyde or CA) with known therapeutic-potential worked-well to balance food efficiency-ratio and Hb- counts closer to control. The fat-soluble phytochemical mono-terpenoid (CA) promoted constitutive mono-hexose (glucose) consuming catabolic-cycles via mono-glycoprotein (insulin) signal-transduction. It resolved diabetogenic-upsurge of gluconeogenic-enzymes, reduced non-sugar (amino/fatty acids) utilization by restricting transamination/dephosphorylation and restored liver-glycogen reserves near to normal-group effectively at 10 mg/kg b.w dose. Conclusions: Hence, the nutraceutical-potential (anti-diabetes/transaminitis ability) of administered exogenous redox-active agent CA can be entertained for evoking therapeutic-heath in diabetic human-community.

Keywords